BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10721684)

  • 1. Use of slow-release melatonin in treatment-resistant depression.
    Dalton EJ; Rotondi D; Levitan RD; Kennedy SH; Brown GM
    J Psychiatry Neurosci; 2000 Jan; 25(1):48-52. PubMed ID: 10721684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects.
    Levitan RD; Shen JH; Jindal R; Driver HS; Kennedy SH; Shapiro CM
    J Psychiatry Neurosci; 2000 Sep; 25(4):337-46. PubMed ID: 11022398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
    Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
    J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation.
    Licht RW; Qvitzau S
    Psychopharmacology (Berl); 2002 May; 161(2):143-51. PubMed ID: 11981594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study.
    Hantouche EG; Akiskal HS; Lancrenon S; Chatenêt-Duchêne L
    J Affect Disord; 2005 Feb; 84(2-3):243-9. PubMed ID: 15708422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
    Jahn H; Schick M; Kiefer F; Kellner M; Yassouridis A; Wiedemann K
    Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression.
    Baune BT; Caliskan S; Todder D
    Hum Psychopharmacol; 2007 Jan; 22(1):1-9. PubMed ID: 17191266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variables influencing antidepressant medication adherence for treating outpatients with depressive disorders.
    Lee MS; Lee HY; Kang SG; Yang J; Ahn H; Rhee M; Ko YH; Joe SH; Jung IK; Kim SH
    J Affect Disord; 2010 Jun; 123(1-3):216-21. PubMed ID: 19914719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician- and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trial.
    Pandina GJ; Revicki DA; Kleinman L; Turkoz I; Wu JH; Kujawa MJ; Mahmoud R; Gharabawi GM
    J Affect Disord; 2009 Nov; 118(1-3):139-46. PubMed ID: 19321206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6 mg) or placebo for sleep disturbance and depressed mood.
    Serfaty MA; Osborne D; Buszewicz MJ; Blizard R; Raven PW
    Int Clin Psychopharmacol; 2010 May; 25(3):132-42. PubMed ID: 20195158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder.
    Munizza C; Olivieri L; Di Loreto G; Dionisio P
    Curr Med Res Opin; 2006 Sep; 22(9):1703-13. PubMed ID: 16968574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression.
    Schmidt PJ; Daly RC; Bloch M; Smith MJ; Danaceau MA; St Clair LS; Murphy JH; Haq N; Rubinow DR
    Arch Gen Psychiatry; 2005 Feb; 62(2):154-62. PubMed ID: 15699292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical effect of nemifitide, a novel pentapeptide antidepressant, in the treatment of severely depressed refractory patients.
    Feighner JP; Sverdlov L; Hlavka J; Nicolau G; Cartwright K; Freed JS
    Int Clin Psychopharmacol; 2008 Jan; 23(1):29-35. PubMed ID: 18090505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quetiapine augmentation of treatment-resistant depression: a comparison with lithium.
    Dorée JP; Des Rosiers J; Lew V; Gendron A; Elie R; Stip E; Tourjman SV
    Curr Med Res Opin; 2007 Feb; 23(2):333-41. PubMed ID: 17288688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
    Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
    J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
    Mouchabac S; Ferreri M; Cabanac F; Bitton M
    Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term tolerability and effectiveness of duloxetine in the treatment of major depressive disorder.
    Dunner DL; Wilson M; Fava M; Kornstein S; Munoz R; O'Reardon J; Trivedi M; Wohlreich M
    Depress Anxiety; 2008; 25(5):E1-8. PubMed ID: 17621644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression.
    Liebrenz M; Stohler R; Borgeat A
    World J Biol Psychiatry; 2009; 10(4 Pt 2):640-3. PubMed ID: 17853274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, controlled trial of duloxetine alone vs. duloxetine plus a telephone intervention in the treatment of depression.
    Perahia DG; Quail D; Gandhi P; Walker DJ; Peveler RC
    J Affect Disord; 2008 May; 108(1-2):33-41. PubMed ID: 17905442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.